Overview of hidradenitis suppurativa:
Hidradenitis Suppurativa (HS), also known as Acne vulgaris, teeth a Chronic inflammatory skin disease characterized by the formation of Deep nodules, abscesses, drainage tracts, and fibrous scars. Lesions occur primarily in the following locations: the Gap Area and rich areas Apocrine glands, etc. Axilla, groin, perianal, perineum, inframammary area。
This condition occurs due to the following reasons: Defective hair follicles blocked and burstCausesRelease of keratin and bacteria into the dermis, which in turnInflammatory response. Get Involved: Neutrophils and lymphocytes. This inflammation can lead to: Abscess formation and damage to the pilosebaceous unit and the surrounding organisation.
Now, there is no cure for HS, and the Prognosis may vary. Often worsensDelayed diagnosis and inappropriate treatmentOther risk factorsSmoking and obesity. This can lead to a worsening of the condition, emphasizing the importance of early diagnosis and intervention. Management of HS includes: a Multidisciplinary approach, dermatologists, surgeons, and other medical professionals are involved.
For more insights into the Hidradenitis Suppurativa pipeline, visit the Report @
Key Takeaways from the Hidradenitis Suppurativa Pipeline Report:
DelveInsight's Hidradenitis Suppurativa Pipeline report reveals a dynamic and active pipeline of over 24 leading companies developing over 24 therapeutic options for the treatment of Hidradenitis Suppurativa.InflaRx、Novartis、UCB、ChemoCentryx、Eli Lilly and Company、Janssen Biotech、AbbVie、Pfizer、Amgen、Incyte Corporation、CSL Behring、Kymera Therapeutics、Lytix Biopharma、Aclaris Therapeutics、Boehringer Ingelheim、Azora Therapeutics. Researchers such as these are currently evaluating new therapies for HS and working to improve the treatment status. Promising treatment candidates in various stages of development include: Bilobelimab, Secukinumab, Avacopan, Imsidolimab, Spesolimab, others.
Recent advances in the Hidradenitis Suppurativa pipeline:
In April 2022、 Ascentage Pharma shared that it is a combination of Palbociclib and APG-2449 that effectively inhibited mesothelioma tumor growth. Induction of autophagy and promotion of cellular senescence. This preclinical data demonstrates that: APG-2449 When combined with CDK4/6 inhibitors, may be possible to treat mesothelioma, and further clinical studies are needed. April 2022、 Anaptis BioWe presented data about Imsidolimab (formerly ANB019), anti-IL-36R antibody under development Generalized pustular psoriasis (GPP) and moderate to severe hidradenitis suppurativa (HS). The company expects top-line results from the HARP Phase 2 trial for HS to be available in the third quarter of 2022.February 2022、 InfraX reported new findings about Vilobelimab (IFX-1), anti-C5a antibodies. Elevated baseline C5a levels were observed in patients with: Moderate to severe Hurley stage II and III HSThis suggests that it may be an effective treatment for Hidradenitis suppurativa。
Hidradenitis Suppurativa Pipeline Analysis:
The report provides comprehensive insights into:
Detailed information about the key companies developing therapies in the Hidradenitis Suppurativa market.
Analysis of pipeline therapeutic candidates categorized by development stage (early, mid and late stage).
Assessment of active and inactive (dormant or discontinued) projects of key companies.
Overview of emerging medicines categorized by development stage, route of administration, target receptor, monotherapy or combination therapy, mechanism of action and molecule type.
A detailed analysis of collaborations, licensing agreements, and funding details driving the progress of the Hidradenitis Suppurativa market.
Download the free sample report to get detailed insights into the Hidradenitis Suppurativa pipeline:
New treatments for hidradenitis suppurativa:
Vilobelimab: InfraX
Secukinumab: Novartis
Abacopan: ChemoCentrix
Imcidoli: Anaptis Bio
Spesolimab: Boehringer Ingelheim
Hidradenitis Suppurativa Major Companies:
More than two dozen prominent companies are working on treating hidradenitis suppurativa.InfraX, Phase III clinical trials provide cutting-edge treatments.
DelveInsight reports cover a wide range of clinical development stages.
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early Stage Products (Phase I)
Preclinical and discovery stage candidates
Discontinued and inactive candidates
Hidradenitis Suppurativa Pipeline Evaluation by Route of Administration (ROA)We categorize our products as follows:
Intravenous
Subcutaneous
Oral
Intramuscular
Further, the pipeline therapies are segmented as follows: Molecular Type, like:
Monoclonal antibodies
Low molecular weight
peptide
To learn more about the Hidradenitis Suppurativa treatment landscape, download a free sample of the report:
Hidradenitis Suppurativa Pipeline Treatment Evaluation:
Evaluation of Hidradenitis Suppurativa by Product Type
Evaluation of hidradenitis suppurativa by stage of development
Evaluation of Hidradenitis Suppurativa by Route of Administration
Evaluation of Hidradenitis Suppurativa by Molecular Type
Download Hidradenitis Suppurativa Treatment Evaluation ReportFor deeper insight into the therapeutic market:
Table of contents
1. Introduction to the report
2. Executive Summary
3. Current treatment patterns for hidradenitis suppurativa
4. Hidradenitis Suppurativa – DelveInsight Analytics Perspective
5. Treatment evaluation
6. Hidradenitis Suppurativa Late-stage Products (Phase III)
7. Hidradenitis Suppurativa Mid-stage Products (Phase II)
8. Early Stage Products (Phase I)
9. Preclinical and discovery stage products
10. Inactive Products
11. Dormant products
12. Discontinued Hidradenitis Suppurativa Products
13. Hidradenitis Suppurativa Product Profile
14.Major Hidradenitis Suppurativa Companies
15. Main products of hidradenitis suppurativa
16. Inactive and Discontinued Products
17. Hidradenitis Suppurativa Unmet Need
18. Future outlook for hidradenitis suppurativa
19. Hidradenitis Suppurativa Analyst Review
20. Appendix
21. Reporting Methods
Contact Information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading business consultancy and market research firm focused on life sciences, supporting pharmaceutical companies by providing comprehensive end-to-end solutions to improve their business performance.
